X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PLETHICO PHARMA NATCO PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 23.5 -1.1 - View Chart
P/BV x 17.8 0.0 106,089.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
PLETHICO PHARMA
Mar-14
NATCO PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs877395 222.1%   
Low Rs42431 1,353.0%   
Sales per share (Unadj.) Rs223.4604.4 37.0%  
Earnings per share (Unadj.) Rs31.132.5 95.7%  
Cash flow per share (Unadj.) Rs40.351.3 78.5%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.5473.6 46.4%  
Shares outstanding (eoy) m33.0734.08 97.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.90.4 825.4%   
Avg P/E ratio x20.96.6 319.0%  
P/CF ratio (eoy) x16.14.2 388.9%  
Price / Book Value ratio x3.00.5 658.3%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5047,262 296.1%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1281,596 70.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,38920,598 35.9%  
Other income Rs m167386 43.3%   
Total revenues Rs m7,55620,984 36.0%   
Gross profit Rs m1,7932,818 63.6%  
Depreciation Rs m304642 47.4%   
Interest Rs m3661,593 23.0%   
Profit before tax Rs m1,290969 133.2%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309-138 -223.1%   
Profit after tax Rs m1,0271,107 92.8%  
Gross profit margin %24.313.7 177.4%  
Effective tax rate %23.9-14.3 -167.5%   
Net profit margin %13.95.4 258.8%  
BALANCE SHEET DATA
Current assets Rs m3,68118,877 19.5%   
Current liabilities Rs m3,12311,896 26.3%   
Net working cap to sales %7.633.9 22.3%  
Current ratio x1.21.6 74.3%  
Inventory Days Days8936 249.0%  
Debtors Days Days59198 29.7%  
Net fixed assets Rs m7,6859,861 77.9%   
Share capital Rs m331341 97.1%   
"Free" reserves Rs m6,67012,331 54.1%   
Net worth Rs m7,25916,139 45.0%   
Long term debt Rs m9554,706 20.3%   
Total assets Rs m11,95733,146 36.1%  
Interest coverage x4.51.6 281.2%   
Debt to equity ratio x0.10.3 45.1%  
Sales to assets ratio x0.60.6 99.4%   
Return on assets %11.78.1 143.1%  
Return on equity %14.26.9 206.4%  
Return on capital %20.712.3 168.6%  
Exports to sales %39.421.4 184.1%   
Imports to sales %5.715.2 37.4%   
Exports (fob) Rs m2,9084,402 66.1%   
Imports (cif) Rs m4213,136 13.4%   
Fx inflow Rs m3,4454,402 78.3%   
Fx outflow Rs m7033,184 22.1%   
Net fx Rs m2,7431,219 225.1%   
CASH FLOW
From Operations Rs m1,4402,437 59.1%  
From Investments Rs m-1,089-6,265 17.4%  
From Financial Activity Rs m-3532,490 -14.2%  
Net Cashflow Rs m-1-1,337 0.1%  

Share Holding

Indian Promoters % 52.0 82.7 62.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.3 182.3%  
FIIs % 16.6 5.5 302.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 7.5 346.7%  
Shareholders   25,395 10,665 238.1%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  SUVEN LIFE  WYETH LTD  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS